The MHRA has released a Drug Safety Update regarding new restrictions and precautions for fluoroquinolone antibiotics.
Disabling, long-lasting, or potentially irreversible adverse reactions affecting musculoskeletal and nervous systems have been reported very rarely with fluoroquinolone antibiotics.
Fluoroquinolone treatment should be discontinued at the first signs of a serious adverse reaction, including tendon pain or inflammation.
Further advice for healthcare professionals and actions to take are available on the MHRA website.